Role of circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents
Latest Information Update: 18 Jun 2021
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- 18 Jun 2021 New trial record
- 01 Jun 2021 Results published in the Cancer Immunology Immunotherapy